Oracle (ORCL) Stock Could Be 49.5% Undervalued Despite Cloud Capex Concerns

Advertisement

Oracle stock reacts as investors reassess recent performance

Oracle (ORCL) stock is drawing attention as investors weigh its recent share performance against the company’s current financial profile, which includes revenue of US$67.36b and net income of US$16.98b.

See our latest analysis for Oracle.

At a share price of US$188.33, Oracle has seen its share price return fall 2.24% over the past day and 8.49% over the past week. However, its 90 day share price return of 23.17% and 3 year total shareholder return of 59.87% indicate that longer term momentum has been stronger than the recent pullback.

If Oracle’s recent moves have you thinking about where else growth and cash generation might show up, this is a good moment to scan 61 profitable AI stocks that aren't just burning cash

With Oracle’s shares pulling back over the past month but still showing strong multi year returns, the key question now is whether the current valuation still leaves upside on the table or whether the market is already pricing in future growth.

Most Popular Narrative: 49.5% Undervalued

According to the most followed narrative on Oracle, a fair value of $373.13 per share sits well above the last close at $188.33, which sets up a very different picture to the recent pullback in the stock.

Operating cash flow remains robust: $20.8 billion in FY2025, up from $18.7 billion in FY2024. However, free cash flow has evaporated. After generating $11.8 billion in FY2024, Oracle posted negative FCF (-$0.4 billion) in FY2025 and deeply negative quarterly FCF in FY2026 (for example, -$11.5 billion in Q3).

Read the complete narrative.

The fair value hinges on how Oracle’s earnings power intersects with its heavy cloud capex, future margin profile, and the way recurring cash flows are expected to rebuild after this spend heavy phase. Short assumptions, big implications.

Result: Fair Value of $373.13 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Oracle’s heavy AI capex and reliance on a handful of large cloud deals could pressure free cash flow and quickly challenge this view that the stock is undervalued.

Find out about the key risks to this Oracle narrative.

Next Steps

With Oracle presenting both clear risks and appealing rewards, this is a moment to look through the numbers yourself and decide where you stand. Then weigh how those risks and rewards balance out with the help of 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Oracle?

If Oracle stock has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to spot other opportunities before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NYSE:ORCL

Oracle

Offers products and services that build, run and support enterprise information technology frameworks worldwide.

Exceptional growth potential, undervalued and pays a dividend.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1155.3% undervalued
51 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative
BL
BlackGoat
IREN logo
BlackGoat on IREN ·

IREN's Bold Moves in Sustainable Bitcoin Mining & AI Data Centers

Fair Value:US$71.4849.2% undervalued
204 users have followed this narrative
6 users have commented on this narrative
32 users have liked this narrative
HE
HedgeY
ARM logo
HedgeY on Arm Holdings ·

The Architecture Layer of AI Computing - But Priced Like the Future Already Arrived?

Fair Value:US$43038.1% undervalued
9 users have followed this narrative
1 users have commented on this narrative
3 users have liked this narrative
HI
Hidden_Rock_Capital
FISV logo
Hidden_Rock_Capital on Fiserv ·

Temporary "perfect storm" leads to opportunity to buy financial services leader for less than 5x long-term earnings

Fair Value:US$119.9956.4% undervalued
13 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative

Updated Narratives

NE
AIIO logo
newsfinder11221 on Robo.ai ·

Robo.ai (NASDAQ: AIIO): Building the Infrastructure Behind the AI Revolution

Fair Value:US$540.4% undervalued
1 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative
EU
European_Hidden_Gem_Stocks
ALMIN logo
European_Hidden_Gem_Stocks on MINT Société anonyme ·

Mint SA: A French Micro-Cap Energy Retailer Worth Watching

Fair Value:€1153.1% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KA
kaspertidemann
BARDJU logo
kaspertidemann on BAR DJUS ·

The Best Season Is Still Ahead

Fair Value:DKK 4.120.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.917.3% undervalued
86 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28029.8% undervalued
195 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.7% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0